Literature DB >> 14993933

Liver X receptors as potential therapeutic targets for multiple diseases.

Guoqing Cao1, Yu Liang, Xian-Cheng Jiang, Patrick I Eacho.   

Abstract

Liver X receptor alpha (LXRalpha) and liver X receptor beta(LXRbeta are oxysterol receptors that regulate multiple target genes involved in cholesterol homeostasis. Recent studies also suggest that the pair of receptors may also be involved in glucose metabolism, inflammation and Alzheimer's disease by regulating critical molecules involved in these pathophysiological processes. Although the prototypic LXR agonists induce liver triglyceride accumulation by regulating the hepatic lipogenesis pathway, it is hoped that a subtype-specific agonist or selective modulators would provide the desired cardioprotection and other benefits without the undesirable concomitant induction of lipogenesis. This review intends to summarize the most recent progress in the field and provide an assessment of LXRs as potential therapeutic targets. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993933     DOI: 10.1358/dnp.2004.17.1.829024

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  14 in total

1.  Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8).

Authors:  J Mark Brown; Liqing Yu
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2009-03

Review 2.  Protein mediators of sterol transport across intestinal brush border membrane.

Authors:  J Mark Brown; Liqing Yu
Journal:  Subcell Biochem       Date:  2010

3.  Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.

Authors:  Natalia Mast; Yong Li; Marlin Linger; Matthew Clark; Jeffrey Wiseman; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2013-12-18       Impact factor: 5.157

4.  A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.

Authors:  Dacheng Peng; Richard A Hiipakka; Jing-Tian Xie; Qing Dai; John M Kokontis; Catherine A Reardon; Godfrey S Getz; Shutsung Liao
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 5.  Mitochondrial function and regulation of macrophage sterol metabolism and inflammatory responses.

Authors:  Annette Graham; Anne-Marie Allen
Journal:  World J Cardiol       Date:  2015-05-26

Review 6.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

7.  Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice.

Authors:  Dacheng Peng; Richard A Hiipakka; Jing-Tian Xie; Catherine A Reardon; Godfrey S Getz; Shutsung Liao
Journal:  Atherosclerosis       Date:  2009-07-08       Impact factor: 5.162

8.  Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.

Authors:  Dacheng Peng; Richard A Hiipakka; Qing Dai; Jian Guo; Catherine A Reardon; Godfrey S Getz; Shutsung Liao
Journal:  J Pharmacol Exp Ther       Date:  2008-08-22       Impact factor: 4.030

9.  Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines.

Authors:  Z X Meng; Y Yin; J H Lv; M Sha; Y Lin; L Gao; Y X Zhu; Y J Sun; X Han
Journal:  Diabetologia       Date:  2012-03-14       Impact factor: 10.122

10.  Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity.

Authors:  Jihong Xu; Gail Wagoner; James C Douglas; Paul D Drew
Journal:  J Leukoc Biol       Date:  2009-08       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.